Alsufyani Hadeel A, Alrefaie Zienab
Department of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt.
J Microsc Ultrastruct. 2020 Dec 10;8(4):148-151. doi: 10.4103/jmau.jmau_105_20. eCollection 2020 Oct-Dec.
The role of the renin-angiotensin system (RAS) and its pharmacological modulators in the susceptibility and outcomes of SARS CoV-2 pandemic (COVID-19) has been much discussed recently. Angiotensin-converting enzyme type 2 (ACE2) has attracted much attention and debate in relevance to COVID-19. It not only acts as the receptor to which the SARS CoV-2 virus binds to be introduced into cells but also balances the effects of angiotensin II offering anti-inflammatory and antifibrotic protective actions to different organs. This mini-review aims to shed some light on the possible involvement of ACE2 and RAS alternate pathways in the comorbidities and clinical findings observed in COVID-19 patients.
肾素-血管紧张素系统（RAS）及其药理调节剂在严重急性呼吸综合征冠状病毒2大流行（COVID-19）的易感性和结局中的作用，近来已被广泛讨论。2型血管紧张素转换酶（ACE2）在与COVID-19相关的研究中备受关注并引发了诸多争论。它不仅是严重急性呼吸综合征冠状病毒2病毒结合并进入细胞的受体，还能平衡血管紧张素II的作用，为不同器官提供抗炎和抗纤维化的保护作用。本综述旨在阐明ACE2和RAS替代途径可能参与COVID-19患者的合并症及临床症状。
